NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $12.68 -0.27 (-2.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.68 +0.01 (+0.04%) As of 08/8/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Edgewise Therapeutics Stock (NASDAQ:EWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Edgewise Therapeutics alerts:Sign Up Key Stats Today's Range$12.46▼$13.1850-Day Range$12.61▼$15.7552-Week Range$10.60▼$38.12Volume568,056 shsAverage Volume603,562 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$40.64Consensus RatingModerate Buy Company Overview Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Read More Edgewise Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreEWTX MarketRank™: Edgewise Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 677th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingEdgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Edgewise Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -8.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.36% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Edgewise Therapeutics has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.36% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Edgewise Therapeutics has recently decreased by 12.56%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.48 News SentimentEdgewise Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Edgewise Therapeutics this week, compared to 6 articles on an average week.MarketBeat Follows2 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.20% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Edgewise Therapeutics' insider trading history. Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTXAugust 9 at 12:38 PM | globenewswire.comWe're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn RateAugust 8 at 8:35 AM | finance.yahoo.comGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.August 10 at 2:00 AM | Priority Gold (Ad)Edgewise Therapeutics Advances in Muscular Dystrophy TrialsAugust 8 at 2:12 AM | tipranks.comEdgewise Therapeutics shares surge as Q2 loss narrows, beats estimatesAugust 7 at 2:51 PM | za.investing.comEdgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7 at 8:00 AM | prnewswire.comEdgewise Therapeutics (EWTX) Projected to Post Earnings on ThursdayAugust 7 at 2:15 AM | americanbankingnews.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesAugust 6, 2025 | prnewswire.comSee More Headlines EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $26.70 at the beginning of 2025. Since then, EWTX shares have decreased by 52.5% and is now trading at $12.68. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.08. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional investors include Geode Capital Management LLC (1.71%), Aberdeen Group plc (0.42%), Candriam S.C.A. (0.21%) and Campbell & CO Investment Adviser LLC (0.11%). Insiders that own company stock include Orbimed Advisors Llc, Peter A Thompson, Holdings A/S Novo, R Michael Carruthers, Joanne M Donovan, Kevin Koch, Alan J Russell, Behrad Derakhshan, Jonathan C Fox, Marc Semigran and John R Moore. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edgewise Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings8/07/2025Today8/10/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EWTX CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Edgewise Therapeutics$40.64 High Price Target$51.00 Low Price Target$14.00 Potential Upside/Downside+220.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$133.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.81% Return on Assets-31.13% Debt Debt-to-Equity RatioN/A Current Ratio20.99 Quick Ratio20.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book2.62Miscellaneous Outstanding Shares105,200,000Free Float80,794,000Market Cap$1.33 billion OptionableOptionable Beta0.26 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:EWTX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.